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Background: Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (KPC-KP) has
become one of the most important contemporary pathogens, especially in endemic areas.
Aims: To provide practical suggestion for physicians dealing with the management of KPC-KP infections
in critically ill patients, based on expert opinions.
Sources: PubMed search for relevant publications related to the management of KPC-KP infections.
Contents: A panel of experts developed a list of 12 questions to be addressed. In view of the current lack
of high-level evidence, they were asked to provide answers on the bases of their knowledge and
experience in the ﬁeld. The panel identiﬁed several key aspects to be addressed when dealing with KPC-
KP in critically ill patients (preventing colonization in the patient, preventing infection in the colonized
patient and colonization of his or her contacts, reducing mortality in the infected patient by rapidly
diagnosing the causative agent and promptly adopting the best therapeutic strategy) and provided
related suggestions that were based on the available observational literature and the experience of panel
members.
Implications: Diagnostic technologies could speed up the diagnosis of KPC-KP infections. Combination
treatment should be preferred to monotherapy in cases of severe infections. For nonecritically ill pa-
tients without severe infections, results from randomized clinical trials are needed for ultimatelyseases Clinic, Department of Medicine University of Udine and Azienda Sanitaria Universitaria Integrata, Presidio
dia, Piazzale Misericodia 15-33100, Udine, Italy.
etti).
Ill Patients Study Group of the European Society of Clinical Microbiology and Infectious Disease (ESCMID), Hellenic
i Terapia Antinfettiva (SITA).
biology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Clinical question deﬁned by panel and related answer
Question no. Question
1 How can the laboratory speed up KP
identiﬁcation and susceptibility testi
2 What is currently the best treatment
infections?
3 What is the role of carbapenems in t
treatment of KPC-KP infections?
4 What molecules can be used to trea
infections?
5 What is the role of nebulized antibio
treatment of VAP and VAT by KPC-K
6 Is prolonged infusion of b-lactams pr
KPC-KP?
7 What about source control in patien
KPC-KP infections?
8 What is the optimal duration of trea
KPC-KP infections?
9 Can KPC-KP infections be prevented
10 Who among KPC-KP colonized patie
increased risk of developing KPC-KP
11 Is decolonization a useful strategy in
colonized patients?
12 What's new in KPC-KP treatment op
KPC-KP, Klebsiella pneumoniae carbapenemase-produ
associated tracheobronchitis.weighing beneﬁts and costs of using combinations rather than monotherapy. Multifaceted infection
control interventions are needed to decrease the rates of colonization and cross-transmission of KPC-KP.
M. Bassetti, Clin Microbiol Infect 2018;24:133
© 2017 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.Introduction
Management of infections caused by multidrug-resistant bac-
teria greatly affects health costs and has become amajormodiﬁer of
health expenses in the ongoing antibiotic resistance crisis [1].
Klebsiella pneumoniae carbapenemase (KPC)-producing
K. pneumoniae (KPC-KP), has become one of the most important
contemporary pathogens, especially in endemic areas [2e4]. The
optimal treatment for KPC-KP, however, is not known, and there are
currently no published recommendations for the management of
infections by KPC-KP. Given the observational nature of most of the
studies on this topic, many of the recommendations listed here
arise from the acquired experience of the invited panel members
and therefore represent expert opinion.Purpose and methods
We sought to answer practical questions for physicians dealing
with the treatment of KPC-KP infections in critically ill patients in
view of the fragmentation in the observational literature on thiss based on expert opinion
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only in selected cases
tions? Novel compounds tar
including meropenem
Among these merope
and favourable result
cing K. pneumoniae; MIC, minimumtopic and the lack of randomized clinical trials [5]. A panel of 11
experts developed a list of questions to be addressed; 12 questions
were formulated after rounds of discussion between chairs (MB, GP,
CV and HG) and panel members. In view of the lack of high-level
evidence, panel members were asked to provide narrative an-
swers on the basis of their knowledge and experience in the ﬁeld.
Finally, provided answers were reviewed and discussed by the
panel until a consensus was reached. The ﬁnal summary of selected
questions and related answers is presented in Table 1.Background information for provided answers
How can the laboratory speed up KPC-KP identiﬁcation and
susceptibility testing?
Rapid methods for identiﬁcation of strains producing KPC and
other carbapenemases are important to ensure appropriate and
early initiation of speciﬁc therapy, as well as the prompt
implementation of the most appropriate infection control mea-
sures [6]. This is particularly relevant with KPC-KP or other typesies could speed up the diagnosis of KPC-KP infections and potentially improve
wever, whether they should be introduced into the laboratory workﬂow remain a
balanced locally, according to the available resources and personnel in each
nt should be preferred to treat KPC-KP infections compared to monotherapy in the
ons and for critically ill patients. For nonecritically ill patients without severe
randomized clinical trials are needed to ultimately weigh the related beneﬁts and
ction of resistance.
h-dose (e.g. 2 g every hours), prolonged infusion meropenem could be beneﬁcial in
IC is 8 mg/L. For MIC up to 32e64 mg/L, meropenem administration should be
utic drug monitoring is available to monitor optimal drug exposure.
be used in combination treatment against KPC-KP, including aminoglycosides,
e, fosfomycin, ceftazidime/avibactamandcarbapenems inselectedcases (seeTable2).
antibiotics could be useful in selected clinical scenario, especially when there is
g. use of inhaled colistin in VAP due to carbapenem-resistant pathogens).
dynamic optimization in KPC-directed regimens, prolonged infusion should be
dose regimens. To achieve pharmacodynamic optimization in KPC-directed
infusion should be combined with high-dose regimens.
patients with KPC-KP infections are limited, source control in this population has
favourable outcomes and should be performed promptly whenever possible.
or KPC-KP infections should vary according to the source of the infection. Factors
of microbiologic eradication, use of biomarkers and optimization of antibiotic
ed to reduce treatment duration.
control components are needed to decrease the rates of colonization and cross-
KP.
of colonized patients, including surveillance and antimicrobial stewardship
ial and contribute to ensure an early and appropriate treatment in patients with
C-KP carriers is currently not supported by large studies and may be considered
.
geting KPC-KP are under investigation and appear promising for their treatment,
/vaborbactam, imipenem/relebactam, plazomicin, ceﬁderocol and eravacycline.
nem/vaborbactam and plazomicin have already demonstrated some interesting
s in treating KPC-KP infections.
inhibitory concentration; VAP, ventilator-associated pneumonia; VAT, ventilator-
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because commonly used regimens for empiric antimicrobial
chemotherapy do not normally cover for multidrug-resistant
pathogens, except under speciﬁc circumstances (e.g. febrile
neutropenia in a patient who is known to be colonized with KPC-
KP) [7].
Several new diagnostic technologies have recently become
available to allow increased rapidity of microbiologic diagnosis,
including matrix-assisted desorption ionizationetime of ﬂight
mass spectrometry (MALDI-TOF MS), rapid immunochromatog-
raphy, rapid enzymatic assays (such as the Carba NP test), single-
cell automated time-lapse microscopy and molecular bio-
logyebased assays [8e10]. These new technologies may be useful
to reduce the time for pathogen identiﬁcation and antibiotic sus-
ceptibility test.
MALDI-TOF MS has proven successful in rapid bacterial identi-
ﬁcation from isolated colonies or monomicrobial blood cultures.
MALDI-TOF MS can also be used for rapid detection of some
resistance determinants, such as b-lactamases [11]. A mass spec-
trometric b-lactamase assay represents a functional assay that is
based on the direct monitoring of the enzymatic activity of the b-
lactamase and can be performed with bacterial cultures or directly
from freshly tagged positive blood cultures, with results available
after 1 to 4 hours' incubation [11]. Both imipenem and meropenem
can be used in these tests, with meropenem being somewhat more
efﬁcient [12].
This method, however, cannot identify the type of b-lactamase.
Recently the identiﬁcation of a 11109 DaMS peak corresponding to
a gene product of the blaKPC pKpQIL plasmid was found to be useful
in rapid tracking KPC-producing strains [13].
Diagnostic platforms capable of rapid detection of blaKPC genes
based on molecular biology techniques are currently available to
target carbapenemase genes (e.g. Xpert Carba-R or Check-Direct
CPE) in bacterial cultures or rectal swabs [14]. Others can iden-
tify blaKPC and other clinically relevant resistance genes directly
from positive blood culture (e.g. FilmArray BC-ID or Verigene).
Remarkably, in this case, the results are provided in about 1 hour
compared to conventional microbiologic methods that may take
from 12 up to 72 hours [15]. More recently, a polymerase chain
reaction/electrospray ionization-mass spectrometry platform
(Iridica) that detects more than 800 bloodstream infection (BSI)-
relevant pathogens and also blaKPC genes in approximately
6 hours was developed [16].
It should be noted that detection of resistance mechanisms by
molecular biology is useful to rapidly predict potential resistance to
some agents, but it does not provide comprehensive information
about the resistance phenotype of the infecting strain, and con-
ventional antibiotic susceptibility test remains the cornerstone for
selection of deﬁnitive treatment regimens and evaluation of
adequate or inadequate antimicrobial chemotherapy [17]. However,
the rapid detection of some resistance mechanism, and of KPC
genes in particular (the presence of which means most of the time
resistance to carbapenems and even multiresistance), can be useful
for an earlier revision of empiric regimens, which usually do not
cover CPE.
Availability of rapid diagnostic methods is associated with
decreased length of stay, lower mortality and reduced costs in the
long term, provided their implementation is feasible [6]. Indeed, in
some cases, these techniques may represent an unaffordable
expensive add-on to the routine diagnostic laboratory workﬂow, in
terms of reagents and manpower cost, requiring a 24/7 schedule of
sample processing. Furthermore, the information provided for
antibiotic susceptibility test is different from conventional mini-
mum inhibitory concentration (MIC) values and must be suitably
conveyed to the clinician to avoid confusion. Overall, microbiologylaboratories should have protocols for immediate notiﬁcation of
clinical teams whenever a CPE infection is identiﬁed.
What is currently the best treatment for KPC-KP infections?
A necessary premise is that only low-level evidence with a high
risk of bias is available from observational studies regarding the
optimal treatment for KPC-KP infections, thus not allowing deﬁnite
conclusions to be drawn [5,18,19]. In this light, the following
statements are to be weighed cautiously, pending results of ran-
domized clinical trials (NCT01597973 and the AIDA study [20] are,
respectively, ongoing and have been recently completed).
Because monotherapy appeared to be associated with higher
mortality rates compared to combination therapy for the targeted
treatment of KPC-KP in observational studies, the use of combined
regimens should be preferred in patients with severe KPC-KP in-
fections [19,21e25]. Indeed, the positive impact of combination
therapy on survival might be true only in patients with severe in-
fections compared to less severe BSI and in nonbacteraemic intra-
abdominal or urinary tract infections, a fact which is also in line
with the favourable survival effect of combinations recently
observed only in patients with a high INCREMENT-CPE mortality
score [23,25]. In patients at lower risk of mortality, no clear survival
beneﬁt of combinations over monotherapy has been demonstrated.
In these patients, a conservative combination approach might be
used at the beginning, with the option of de-escalating to a simpler
regimen in correlation with patient's clinical conditions. However,
the risk of inducing further resistance by the use of last-resort
antibiotics is a nonnegligible risk, and results from randomized
clinical trials are needed for ultimately weighing beneﬁts and costs
of using combinations in patients with nonsevere KPC-KP
infections.
What is the role of carbapenems in the treatment of KPC-KP
infections?
In combination treatment, meropenem may still be considered
as an option for possibly enhancing bacterial killing, provided that
the MIC of meropenem is 8 mg/L and that a high-dose and pro-
longed infusion regimen is administered. With the limitations of
the nonrandomized design, a survival beneﬁt by using
meropenem-based regimens has indeed been argued in many
observational studies, with published data mostly referring to
meropenem-including combinations for treating KPC-KP BSI. In
large multicentre studies conducted in Italy and Greece, increased
survival by using combinations of meropenemwas observed when
KPC-KP exhibited MICs of 8 mg/L [23,24]. Smaller case series also
suggested that increasing carbapenem dosage, use of prolonged
infusion and therapeutic drug monitoring might be helpful for
treating KPC-producing organisms with meropenem MICs up to 32
to 64 mg/L [26,27]. However, clinical evidence supporting this
possibility is preliminary [26,27], and the combination of two other
agents showing in vitro activity against the given KPC-KP isolate
should be considered as a reasonable alternative to carbapenem-
including regimens. The administration of carbapenem-based
regimens when facing meropenem MICs of >8 mg/L might be
considered for MICs up to 32 to 64 mg/L, provided that therapeutic
drug monitoring is available to monitor optimal drug exposure, in
view of the risk of futility and perpetuation of resistance selection.
Because carbapenem MICs are important for including or not
meropenem in combination antimicrobial regimens against KPC-
KP and other CPE, the accurate measurement of carbapenem
MICs of KPC-KP is a clinically relevant issue. Unfortunately, auto-
mated systems and gradient diffusion tests (which are commonly
used for antibiotic susceptibility tests in diagnostic microbiology)
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KP and other CPE [28]. Therefore, we recommend that carbapenem
MICs of KPC-KP be determined using the reference broth micro-
dilution methodology [29], covering meropenem concentrations
up to at least 32 to 64 mg/L.
What molecules can be used to treat KPC-KP infections?
Complete background information is available as
Supplementary Material S1 [30e68]. A summary of the available
drugs and their suggested dosage for treating KPC-KP infections is
presented in Table 2.
What is the role of nebulized antibiotics in the treatment of
ventilator-associated pneumonia (VAP) and ventilator-associated
tracheobronchitis by KPC-KP?
Inadequate penetration of intravenous antibiotics that may be
used against KPC-KP (including colistin, aminoglycosides and
tigecycline) to the epithelial lining ﬂuid have prompted theTable 2
Antimicrobial agents against KPC-KP
Drug Loading dose Daily dose for normal
renal function
Polymyxins [30e41]
Colistina 9 million IU 4.5 million IU IV every 1
Intrathecal/intraventricu
125 000e250 000 IU
Inhaled: 1 to 3 million
IU every 8 hours
Polymyxin Bb Not required 7500e12 500 IU/kg ever
12 hours every 12 hours
Intrathecal/intraventricu
50 000 IU every 24 hour
Aminoglycosides [42e44]
(https://www.uptodate.com/
contents/manifestations-of-
and-risk-factors-for-
aminoglycoside-nephrotoxicity)
Gentamicin Not required when
administered in pulse
dosing schemes
5 to 7 mg/kg infused
over 1 hour
Amikacin Not required when
administered in pulse
dosing schemes
15 to 20 mg/kg infused
over 1 hour
Tigecycline 100e200 mg 50e100 mg every
12 hours IV
Fosfomycin Not required 18 to 24 g IV in 3 to 4 d
Ceftazidime/avibactam Not required 2.5 g every 8 hours IV
infused over 2 hours
Meropenem 1e2 g 2 g every 8 hours IV
infused over 3e6 hours
BSI, bloodstream infection; ESBL, extended-spectrum b-lactamase; KPC-KP, Klebsiella
concentration.
a One milligram of colistin base activity is contained in 2.4 mg colistimethate, which i
b One milligram of polymyxin B is equivalent to 10 000 IU.administration of aerosolized antibiotic therapy in patients with
VAP [68]. Clinical outcomes were usually noncomparable between
clinical studies as a result of heterogeneity in regimens, indications
(i.e. VAP, ventilator-associated tracheobronchitis, colonization),
therapeutic approaches (intravenous antibiotic and/or nebulized)
and different nebulizing devices used [69,70]. Data on KPC pro-
ducers are scarce overall.
Because maximal antibiotic delivery depends on the type of
aerosol generators, novel drugedevice combinations stand out as a
promising delivery approach in critically ill patients. A randomized
trial compared ﬁxed combination of amikacin and fosfomycin (5:2
ratio) or placebo delivered via the investigational eFlow Inline
System (PARI GmbH, Starnberg, Germany) as adjunctive treatment
to standard intravenous antibiotics [71]. Distribution of multidrug-
resistant and extensively drug-resistant isolates did not differ
statistically between the two arms (ten and ﬁve KPC-KP were
identiﬁed in target and control arms, respectively). Although
clinical beneﬁt was not demonstrated, resistance selection was
prevented and eradication of pathogens was higher in the nebu-
lized arm.Comments
2 hours
lar:
For infections caused by organismswithMIC >0.5mg/L, it is advisable to
use colistin as part of combination therapy. For dosage adjustment in
patients with renal failure, see Nation et al. [41].
y
lar:
s
No dose adjustment for renal failure.
Aminoglycosides can be useful as part of combination regimens for
treating KPC-KP infections, especially if colistin resistance is
documented. Pulse dosing is preferable to multiple daily doses; desired
peak serum levels are about 10 times the MIC of the organism. Adjust
doses according to Hartford nomogram [43].
d
For BSIs or pneumonia or when tigecycline MIC >0.5 mg/L, higher doses
are recommended (loading dose, 200 mg followed by 100 mg every
12 hours), preferably in combination with another agent. Not to be used
in urinary tract infections; no concentrations in urine.
oses Fosfomycin could be used in combination treatment for KPC-KP
infections administered as 6 to 8 g every 8 hours. Resistance can occur
during treatment and should be monitored. Potential of fosfomycin to
select resistant mutants precludes use as single agent.
Approved for Hospital and Ventilator acquired pneumonia, complicated
intra-abdominal and urinary tract infections and for the treatment of
infections due to aerobic Gram-negative organisms in adult patients
when other treatments might not work.; active in vitro against
Enterobacteriaceae-producing ESBLs, AmpC, KPC, OXA-48. Clinical
experience for carbapenem-resistant Enterobacteriaceae is currently
limited to case series [55e58]. Despite concerns of resistance selection
raised by a few reports that might support the used of ceftazidime/
avibactam in combination with other agents for treating KPC-KP
infections, whether it should be ultimately used alone or combined
remain unclear, and requires further dedicated investigation.
Meropenem should be used in combination with another active agent;
the probability of response is higher when meropenem MIC 8 mg/L.
Salvage therapy with association of 2 carbapenems, e.g. ertapenem plus
eithermeropenem or doripenem, can be considered when other options
are not suitable or available.
pneumoniae carbapenemase-producing K. pneumoniae; MIC, minimum inhibitory
s equivalent to 30 000 IU.
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by the European Society of Clinical Microbiology and Infectious
Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP)
[72,73] argue for an unclear clinical beneﬁt of inhaled antibiotic in
VAP due to KPC-producers [68]. A potential impact on resistance,
however, needs to be further investigated [68,74]. Recently pub-
lished guidelines recommend the add-on use of inhaled colistin in
patients with VAP due to carbapenem-resistant pathogens that are
susceptible only to colistin [75]. The recommendation was based
on a meta-analysis of four studies reporting that add-on nebulized
colistin was associated with improved clinical cure. Non-
responding VAP is another indication for add-on nebulized colistin
[73].Is prolonged infusion of b-lactams preferable for KPC-KP?
Prolonged b-lactam infusion is intended to enhance the potency
(i.e. fT >MIC) of these agents against pathogens with elevated MICs
[76]. Because KPC-KP is intrinsically resistant to carbapenems, the
use of a pharmacodynamically optimized regimen that utilizes an
increased dose and infusion time has been advocated as a tech-
nique to maximize in vivo exposures [77,78]. Enhancement of
fT > MIC can be achieved using either continuous (total daily dose
infused over a 24-hour period) or prolonged infusions (conven-
tional 0.5-hour infusion prolonged up to 6 hours [79,80]). Carba-
penem reduced stability at room temperature and requires
frequent replacements of the antimicrobial at each dosing interval
[81,82], but it provides pharmacodynamic optimization and more
ﬂexibility for the nursing staff in patients receiving polypharmacy
and limited intravenous access.What about source control in patients with KPC-KP infections?
The objective of source control includes the actions to control
the foci of infection and to restore optimal function of the site of
infection. Source control includes removal of implanted or
tunnelled devices, open surgical or percutaneous drainage of
infected ﬂuids or abscesses and surgical resection of infected tis-
sues. Time from hypotension to implementation of source control
has been found to be highly correlated with outcome. Therefore,
interventions to be undertaken for source control within the ﬁrst
12 hours after the diagnosis of the septic syndrome, if feasible,
should be considered [83].
Although source control is reported as a modiﬁable predictor of
mortality in sepsis and septic shock [83], the data particularly from
KPC-KP infections are scarce. In a two-match caseecontrol study
including 99 patients in each arm comparing patients with KPC-KP
and carbapenem-susceptible K. pneumoniae, removal of focus of
infection was independently associated with patient survival [84].
In a prospective observational cohort study encompassing 53 pa-
tients with BSI caused by KPC-KP, prior surgery and therapeutic
interventions targeting the removal of the site of infection were
strongly correlated with survival [85]. Similar conclusions were
reported by Falcone et al. [86] in a retrospective analysis with 111
intensive care unit patients with KPC-KP and septic shock in 21.6%
of cases. Source control process was accomplished in 95.2% of pa-
tients who survived in comparison to 31.2% who died. Cox regres-
sion analyses revealed that control of removable source of infection
was associated with favourable outcome (hazard ratio, 0.14;
p < 0.001). In a retrospective study including 48 BSI due to KPC-KP,
adjunctive source control procedures were associated with clinical
response at day 7 (odds ratio, 12.2; 95% conﬁdence interval,
1.4e110; p 0.025) [87].What is the optimal duration of treatment for KPC-KP infections?
Optimal treatment duration for KPC-KP infections is unclear. In
retrospective studies, a mean duration of 2 weeks of treatment was
reported [88]. In VAP, robust data support a reduced 8-day antibi-
otics course in patients receiving appropriate initial empirical
therapy [89e91]. This strategy was associated with signiﬁcantly
more antibiotic-free days without negative impact onmortality and
reduced resistance selection. Higher relapse rates in patients with
nonfermenting Gram-negative bacilli were initially reported, sug-
gesting longer treatments when these pathogens were responsible
for VAP [89]. An updated meta-analysis of VAP caused by non-
fermenters, however, supported a reduced length of treatment (e.g.
7 days), which is currently recommended by guidelines [75].
As far as bacteraemia is concerned, the evidence is even less
clear. Havey et al. [92], in a large systematic review and meta-
analysis encompassing 24 trials, showed that patients receiving
short treatment (5e7 days) versus those receiving long treatment
(7e21 days) for noneStaphylococcus aureus bacteraemias had no
signiﬁcant differences in mortality, microbiologic eradication or
clinical cure. Randomized controlled trials to assess the optimal
duration of bacteraemia in the context of multidrug-resistant and
KPC producers are awaited and may provide baseline evidence that
long treatments may not be necessary. In another meta-analysis,
antibiotic algorithms guided by procalcitonin levels were found
to safely guide reduced treatment duration without any negative
impact on survival [93]. These ﬁndings suggest that a holistic
approach combining adequate sterilization of septic foci (microbi-
ologic eradication), optimization of antibiotic exposure in critically
ill patients and use of biomarkers enabling monitoring of the
effectiveness of administered treatment may allow for shorter
treatment durations even in the presence of KPC producers.
Can KPC-KP infections be prevented? How?
The ESCMID recently released guidelines aimed to decrease the
transmission of multidrug-resistant Gram-negative pathogens
[94,95]. The most robust measure to prevent interpatient trans-
mission of KPC-KP appeared to be hand hygiene [96]. In a study
showing 30% reduction of KPC-KP transmission rate, this achieve-
ment was possible in an 8- to 12-week time frame with active
surveillance, contact precautions and isolation or cohorting, but
only if at least 60% compliance with hand hygiene compliance was
reached.
Additional measures includeminimizing use of invasive devices,
promotion of antimicrobial stewardship, a standardized approach
for active surveillance of at risk populations and protocols for
discontinuation of carrier status.
Routine rectal swab surveillance of KPC-KP contacts is an
important measure to enhance identiﬁcation and isolation of car-
riers, but such surveillance should not be used as an single infection
control measure to prevent KPC-KP dissemination [94,97e99]. In
this regard, multifaceted interventions are more likely to be suc-
cessful. For example, the combination of daily baths with 2%
chlorhexidineeimpregnated wipes, point prevalence surveillance
with swabs, isolation of colonized or infected patients, cohorting of
medical personnel, enhanced environmental surveillance and re-
petitive educational campaigns successfully controlled the further
horizontal spread of a monoclonal KPC-KP strain [100]. In another
study, transmission through contaminated sinks has been sug-
gested as the major responsible for a long-term, low-frequency
hospital outbreak of KPC-KP infections, further conﬁrming the need
for accurate environmental surveillance and disinfection [101]. In a
study from Israel, a signiﬁcant decline of the nosocomial CPE
Table 3
Summary of studies reporting decolonization strategies as means of eradicating KPC-KP carriage
Study Design and population Intervention Main outcome Comment
Zuckerman
2011 [116]
 Pilot study in haemato-oncology and bone
marrow transplant unit (15 patients).
 Goal was to eradicate CRKP from rectal
carriage.
 Oral gentamicin at dose of 80 mg q.i.d. was
administered to all identiﬁed carriers until
eradication.
 Median duration of therapy, 27 days (range, 7
e90 days).
 Eradication rate 66% (10/15) and lasted for
median of 9 months (range, 2e10 months).
 Discontinuation of persistent bacteraemia
occurred in 62.5% (5/8), and nosocomial
spread of CRKP carrier state ceased.
 No gentamicin resistance was detected in
blood isolates during oral gentamicin
treatment.
 Administration of intensive chemotherapy
and SCT was feasible.
Saidel-Odes
2012 [117]
 Randomized, double-blind, placebo-
controlled trial in 1000-bed tertiary-care
university hospital
 Forty adults with CRKP-positive rectal swab
cultures.
 SDD arm received oral gentamicin and
polymyxin E gel (0.5 g 4 times per day) and
oral solutions of gentamicin (80 mg 4 times
per day) and polymyxin E (1  106 units 4
times per day for 7 days).
 Positivity for CRKP rectal cultures was
signiﬁcantly reduced by 2 weeks.
 16.1% in placebo arm and 61.1% in SDD arm
were negative (OR, 0.13; 95% CI, 0.02e0.74;
p < 0.0016). Difference between 2 arms was
still maintained at 6 weeks (33.3% vs. 58.5%).
 No evidence of increase in either gentamicin
or polymyxin E MIC among CRKP isolates.
 SDD was effective as decolonization strategy
for selected patients colonized with CRKP,
such as transplant recipients or
immunocompromised patients pending
chemotherapy and candidates for major
intestinal or oropharyngeal surgery.
Lübbert
2013 [118]
 Single-centre outbreak of KPC-2, affecting 90
patients hospitalized over 28 months.
 Retrospective analysis of patients who
received SDD compared to remaining
patients harbouring KPC-2-KP.
 14 consecutive patients were treated with
short course (7 days) of SDD regimen
consisting of colistin (1 million units q.i.d.)
and gentamicin (80 mg q.i.d.) as oral
solutions, and colistin/gentamicin gel (0.5 g)
to oral cavity.
 Decolonization of KPC-2-KP was achieved in
6 (43%) of 14 patients after mean (range) of
21 (12e40) days, but was also observed in 23
(30%) of 76.
 Secondary resistance to colistin (by 19%) and
gentamicin (by 45%) was observed in SDD
group but not in comparative group of non-
SDD controls (p 0.102).
 SDD approach was not sufﬁciently effective
for decolonization and was associated with
high rates of resistance in subsequent
cultures.
Tascini
2014 [119]
 Pilot nonblinded, prospective study in 3
Italian hospitals to assess feasibility of
administering oral gentamicin for KPC-KP.
 Gut decontamination.
 Patients enrolled had gut colonization by
gentamicin-susceptible KPC-KP and were
candidates for planned surgery, major medi-
cal intervention or patient transfer.
 Oral gentamicin, 80 mg 4 times daily, was
administered to 50 consecutive patients
over 8-month period.
 Separate analysis was performed with 23
patients receiving oral gentamicin alone and
27 patients who received CSAT.
 Oral gentamicin provided for median (IQR) 16
(10e27) days.
 KPC-KP infections documented in 5 (15%) of
34 successfully decontaminated patients
compared to 12 (73%) of 16 persistent carriers
(p < 0.001).
 Decontamination rate was 96% (22/23) in
patients receiving oral gentamicin only
compared to 44% (12/27) treated with oral
gentamicin and CSAT (p < 0.001).
 Gentamicin-resistant KPC-KP strains were
isolated from stools of 4 of 16 persistent
carriers
 Useful for gut decontamination and
prevention of infection due to KPC-KP, espe-
cially in patients not receiving CSAT.
 No difference in overall mortality was
observed between decontaminated and
persistently colonized patients.
Oren
2013 [120]
 Semirandomized prospective controlled trial
was conducted to eradicate CRE colonization
using oral nonabsorbable antibiotics.
 152 patients were included; 50 patients
received 1 of 3 drug regimens: gentamicin,
26; colistin, 16; both drugs, 8, followed for
median duration of 33 days; 102 were
followed for spontaneous eradication for
median duration of 140 days (controls).
 Antibiotic selection was based on isolate's
in vitro susceptibility.
 Eradication rates in 3 treatment groups were
42%, 50%, and 37.5%, each signiﬁcantly higher
than 7% spontaneous eradication rate in
control group (p < 0.001, <0.001, and 0.004)
with no difference between regimens.
 No signiﬁcant adverse effects were observed.
 Administration of oral nonabsorbable
antibiotics was effective and safe for
eradication of CRE colonization and thus may
reduce patient-to-patient transmission and
incidence of clinical infection.
 Trend towards lower mortality among
patients who experienced eradication while
receiving treatment (2/22, 9%) compared to
those who did not experience eradication (9/
28, 32%) was observed (p 0.052).
Tascini
2015 [121]
 1:1 caseecontrol study exploring prevention
of KPC-KP gut colonization in patients who
undergo hepatectomy with oral gentamicin
in endemic setting.
 All 31 consecutive patients who underwent
liver resections in last year treated were
orally with gentamicin; controls comprised
31 patients who underwent surgery in same
ward in previous year without gentamicin
prophylaxis.
 Overall gut colonization rate in intervention
group was 3% (1/31) vs. 29% (9/31) in
control group (p 0.016).
 Only KPC-KP strain isolated in gentamicin-
treated group retained susceptibility to
gentamicin.
 Oral administration of gentamicin might be
effective to avoid KPC-KP gut colonization
without adverse events.
Machuca
2016 [122]
 Retrospective cohort study of patients
colonized by.
 KPC-KP in 2 hospitals during outbreak with
colistin-resistant KPC-KP strain, exploring
whether decolonization therapy with ami-
noglycosides had protective effect in selected
patients.
 77 patients at high risk (neutropenia, major
surgery, multiple comorbidities) with rectal
colonization by colistin-resistant KPC-KP
were followed for 180 days.
 Oral aminoglycosides (gentamicin or
combination of neomycin/streptomycin)
were administered to 44 patients.
 At 180 days of follow-up, decolonization was
associated with lower risk of mortality in
multivariate analyses (HR 0.18; 95% CI 0.06
e0.55) and lower risk of KPC-KP infections
(HR 0.14; 95% CI 0.02e0.83) and increased
microbiologic success (HR 4.06; 95% CI 1.06
e15.6). Beneﬁcial effects were more favour-
able with gentamicin.
 Intestinal decolonization with
aminoglycosides is associated with reduction
in crude mortality and KPC-KP infections.
CI, conﬁdence interval; CRE, carbapenem-resistant Enterobacteriaceae; CRKP, carbapenem-resistant Klebsiella pneumoniae; CSAT, concomitant systemic antibiotic treatment; HR, hazard ratio; IQR, interquartile range; KPC,
Klebsiella pneumoniae carbapenemase; KPC-KP, Klebsiella pneumoniae carbapenemaseeproducing K. pneumoniae; MIC, minimum inhibitory concentration; OR, odds ratio; SCT, stem cell transplantation; SDD, selective digestive
decontamination.
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Table 4
New antimicrobials with potential activity against KPC-producing Enterobacteriaceae
Antibiotic Antibiotic class Resistant phenotypes Status of development Company ments
Ceftazidime/
avibactam
b-Lactam/b-lactam
inhibitor
 Activity against Enterobacteriaceae-producing
KPCs, ESBLs, OXA, AmpC enzymes.
 No activity against class B b-lactamases (MBL,
VIM, NDM).
 Avibactam offers no enhanced activity
against Pseudomonas aeruginosa and
Acinetobacter baumannii.
 Noninferiority vs. imipenem and
meropenem in phase 2 clinical trials for
treatment of cUTIs and cIAIs, respectively.
 Licensed in USA and EU for cUTIs, cIAIs
and HAP/VAP.
 Phase 3 study in VAP completed.
 Phase 1 study on pharmacokinetics of
critically ill patients planned.
USA, Allergan;
EU and rest of
the world: Pﬁzer
azidime/avibactam was recently licensed for
tment HAP/VAP, cUTIs, cIAIs in USA and Europe and
he treatment of infections due to aerobic Gram-
tive organisms in adult patients when other
tments might not work [123] (https://clinicaltrials.
ct2/results?
¼ceftazidimeþavibactam&Search¼Search);
stration trials, however, did not include CRE
tes.
Ceftaroline/
avibactam
b-Lactam/b-lactam
inhibitor
 ESBL- and KPC-producing Enterobacteriaceae.
Avibactam effectively inhibits Ambler class A
(e.g. ESBL and KPC), C (AmpC), and some D
(OXA-like) enzymes.
 No activity against A. baumannii or
P. aeruginosa.
 No activity against class B enzymes (MBL).
 Completed phase 1 trials and 1 phase 2
trial in cUTI.
 Completed phase 2 trial in cUTIs vs.
doripenem, and 3 phase 1 trials
awaiting results.
Pﬁzer Laboratories aroline/avibactam has promising in vitro spectrum;
lts from clinical trials are pending [123] (https://
caltrials.gov/ct2/results?
¼ceftarolineþavibactam&Search¼Search).
Imipenem/
relebactam
Carbapenem/
b-lactamase
inhibitor
(diazabicyclooctane)
 Class A and C b-lactamases, porin mutations,
class D (OXA-48 not consistently).
 No activity against MBL.
 Completed phase 2 trial in cUTI; currently
in phase 3 trials vs. colistin against
imipenem-resistant pathogens and vs.
piperacillin/tazobactam in bacterial
pneumonia.
Merck bactam is under investigation in combination with
enem/cilastatin with phase 3 trials underway vs.
tin for imipenem-resistant pathogens and vs.
racillin/tazobactam in bacterial pneumonia
123] (https://clinicaltrials.gov/ct2/results?
¼imipenemþrelebactam&Search¼Search).
Meropenem/
vaborbactam
(RPX 7009)
Carbapenem/boronic
acidebased b-lactamase
inhibitor
 Class A b-lactamases (KPC and most AmpC).
 No activity against MBL and class D OXA-48.
 Completed phase 3 trial in cUTI.
 Completed phase 3 trial in various
infections caused by
carbapenemresistant bacteria
and approved by FDA.
 Planned phase 3 trial in VAP.
Medicines
Company
nic-based b-lactamase inhibitor vaborbactam
bined with meropenem (Carbavance) currently in
se 3 trials [62] (https://clinicaltrials.gov/ct2/results?
¼carbavance&Search¼Search).
Plazomicin New aminoglycoside
(neoglycoside)
 Various Gram-positive and Gram-negative
organisms.
 Not active against bacteria harbouring
ribosomal methyltransferases (mostly NDM-
1 strains).
 Completed 2 phase 3 trials (UTIs and
serious infections by CRE).
 Approved by FDA on September 2017.
Achaogen parenteral hemisynthetic aminoglycoside with
urable pharmacokinetics and safety proﬁle,
omicin, holds also promise against KPC producers
123]. Its efﬁcacy against carbapenem-producing
eria has been recently demonstrated in serious
ctions including BSI, HAT/VAP and cUTI (https://
c1.squarespace.com/static/
99d96e4b084d1d0b105c3/t/
6714b8a79b0b91ba96a6/1492870939778/
MIDþ17-EPIC_Final.pdf; https://www.escmid.org/
id_publications/escmid_elibrary/material/?
¼52433).
Ceﬁderocol,
S-649266
Siderophore
cephalosporin
 ESBL, class A (KPC) and class B (NDM-1)
carbapenemases and OXA-type enzymes,
broad range of pathogens including
A. baumannii, P. aeruginosa, Steno-
trophomonas maltophilia and Enterobacteri-
aceae (CRE).
 Completed phase 2 trial in UTI; currently
in phase 3 trials for severe infections by
CRE.
 Phase 3 trial in nosocomial pneumonia
scheduled.
Shionogi derocol (formerly S-649266) is promising
rophore cephalosporin, showing high activity
nst carbapenem-resistant Gram-negative bacteria,
it is currently in phase 3 trial [62,123,124].
(continued on next page)
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M. Bassetti et al. / Clinical Microbiology and Infection 24 (2018) 133e144140acquisition was achieved with a multiple-step strategy, including
ward-based mandatory guidelines for carrier isolation, patient and
staff cohorting, active surveillance and new rules for microbiology
identiﬁcation, direct ofﬁcer visits at healthcare facilities and
networking [102].
An important factor to consider is the presence of so-called
superspreaders (i.e. those carriers who more easily spread KPC-
KP in their immediate environment [93]). Superspreaders are
characterized by high rectal CPE concentrations and are more
frequently admitted for respiratory disease [103]. This effect has
similarities with other enteropathogenetic syndromes such as
Clostridium difﬁcile colitis and candidaemia, at least by themeans of
exogenous colonization [103,104]. In a multicentre US study, KPC-
KP clearance was attributed to a reduction in the use of urinary
catheters, a factor that should be considered in the implementation
of a bundle procedure [105].
Who among KPC-KP colonized patients is at increased risk of
developing KPC-KP infections?
Many studies have focused on the role of KPC-KP colonization in
the development of infection in order to guide the selection of
appropriate interventions and administration of early appropriate
treatment.
In a retrospective study involving ﬁve large Italian hospitals,
bowel colonization by KPC-KP played a major role in predicting
transition from colonization to infection [106]. The overall number
of colonized sites represented the most important risk factor for
KPC-KP BSI development among rectal carriers in a prospective
multicentre study [107,108]. Other risk factors for KPC-KP BSI
included intensive care unit admission, abdominal invasive pro-
cedures, chemotherapy or radiotherapy, and previous BSI [107,109].
In a study including patients undergoing open heart surgery,
colonization was the most important risk factor for KPC-KP infec-
tion [110]. In a prospective cohort study of adult patients under-
going liver transplantation, KPC-KP infection rates among patients
noncolonized, colonized at liver transplantation and colonized after
liver transplantation were 2%, 18.2% and 46.7%, respectively [107].
In settings where colonization with KPC-KP is common among
critically ill patients, antibiotic stewardship programs should be
undertaken to optimize antimicrobial use, as shown by a study
demonstrating high risk of KPC-KP VAP in colonized patients
receiving prolonged antimicrobial therapy [111].
Risk analysis of high mortality rates (64%) among oncohaema-
tologic patients undergoing allogenic transplant has highlighted
the presence of pretransplantation KPC-KP infection and the
absence of active ﬁrst-line antibiotic treatment, identifying the
need for targeted interventions [112]. A subsequent report illus-
trated the safety and efﬁcacy of allogenic haematopoietic stem cell
transplantation in patients colonized by the KPC-KP using the
‘Turin bundle’: avoidance of levoﬂoxacin prophylaxis, treatment
with gentamicin by mouth in the best window of opportunity
before transplantation, administration of tigecycline and piper-
acillin/tazobactam as empiric treatment of febrile neutropenia and
administration of combination regimens (e.g. colistin plus tigecy-
cline plus meropenem) in patients with severe sepsis or septic
shock [113]. In another study, the cumulative incidence of KPC-KP
BSI and septic shock at 1 year after haematopoietic stem cell
transplantation was signiﬁcantly reduced from 62.5% to 16.6% after
the introduction of systematic screening with rectal swabs, contact
precautions and early targeted treatment in neutropenic patients
with fever with at least two antibiotics [114]. Finally, a multifaceted
infection control program was able to reduce both BSI due to CPE
and CPE colonization, whereas monthly incidence of CPE carriage
was predictive of BSI [115].
M. Bassetti et al. / Clinical Microbiology and Infection 24 (2018) 133e144 141Is decolonization a useful strategy in KPC-KP colonized patients?
Studies deploying oral decolonization strategies as a mean to
eradicate gut carriage of KPC-KP have produced conﬂicting results,
and only one reported a survival beneﬁt (Table 3) [116e122]. With
regard to the use of oral gentamicin for decolonization purposes, an
indiscriminate use should be avoided. Indeed, this strategy has a
high risk of failure and also cannot be separated from the risk of
selecting gentamicin resistance (and thus of losing one of the
lastdif not the very lastdtherapeutic options) [119,122]. It should
therefore be reserved for highly selected special conditions (e.g.
very high risk of developing infection because of severe neu-
tropenia or recurrent KPC-KP infections) on a patient-by-patients
basis [122].
What's new in KPC-KP treatment options?
A handful of new compounds expected to address the thera-
peutic problem of KPC-KP in the near future are summarized in
Table 4 (reporting molecules in phase 3 of clinical development)
[123e128].
Conclusions
The optimal management of KPC-KP infections in critically ill
patients relies on a concerted multidisciplinary approach. On a
case-by-case basis, efforts should indeed be directed towards pre-
venting colonization, infection andmortality. Each intervention has
its peculiar issues to be addressed (preventing colonization in the
patient, preventing infection in the colonized patient and coloni-
zation of his or her contacts, reducing mortality in the infected
patient by rapidly diagnosing the causative agent and promptly
adopting the best therapeutic strategy), but all are crucial to ulti-
mately curtail the high mortality of KPC-KP infections. High-level
evidence is urgently needed to ﬁrmly guide physicians through
all these steps.
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